针对心脏纤维细胞可塑性,用于心力衰竭中的抗纤维素和再生疗法
Suchandrima Dutta1,2, Sophie Chen1, Waqas Ahmad1
1Department of Pathology and Laboratory Medicine, College of Medicine, University of Cincinnati, 231 Albert Sabin Way, Cincinati, OH 45267, USA.
Cells
|January 28, 2026
概括
心脏纤维化是心力衰竭的关键因素,涉及慢性伤口愈合和过度的矩阵积累. 了解多样化的心脏纤维细胞行为对于开发用于逆转心脏损伤的新疗法至关重要.
科学领域:
- 心血管生物学 心血管生物学
- 细胞生物学 细胞生物学
- 再生医学是一种再生医学.
背景情况:
- 心脏纤维化,以过度的细胞外基质积累为特征,是心力衰竭 (HF) 的主要驱动因素.
- 心脏纤维细胞 (CFs) 是异质的,在矩阵重塑中扮演着不同的角色,影响正常修复与不适应性痕.
- 最近的转录学研究揭示了不同的CF状态,涉及到矩阵生产,血管生成,免疫信号和机械传感.
研究的目的:
- 审查CF激活在HF发展和进展中的动态.
- 评估导致心脏功能障碍的途径和机制.
- 突出针对CF患者的治疗策略,用于HF治疗和心脏修复.
主要方法:
- 在小鼠模型和人类心脏组织中对最近的单细胞和空间转录组研究进行了审查.
- 对心脏纤维细胞的分子状态和功能作用的分析.
- 评估心肌纤维化和心肌纤维化中的信号通路和机制.
主要成果:
- 心脏纤维细胞表现出多样化的分子状态和专门的作用,重新定义纤维化作为一个动态的过程.
- 治疗转化受到不明确的纤维细胞异质性和缺乏特定标记物的限制.
- 针对CF提供了预防HF和改造增强的潜力.
结论:
- 调节CF活动,准特定的信号通路,或采用再生方法,可以对抗心脏纤维化.
- 将抗纤维素和再生策略与精密医学相结合,有望扭转与HF相关的纤维化.
- 恢复功能性心肌需要一个全面的方法来管理纤维细胞异质性和功能.
相关概念视频
01:22Heart Failure VI: Adjunct Therapies
314
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
314
01:29Heart Failure II: Pathophysiology
872
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
872
01:17Pathophysiology of Heart Failure
3.5K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.5K
01:27Heart Failure I: Introduction
847
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
847
01:22Heart Failure Drugs: Diuretics
948
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
948
01:30Heart Failure V: Medical Management
272
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
272